News
ENTX
2.005
+0.25%
0.005
Weekly Report: what happened at ENTX last week (0415-0419)?
Weekly Report · 4d ago
Why the Market Dipped But Entera Bio Ltd. (ENTX) Gained Today
NASDAQ · 04/18 22:15
GSK Announces FDA Acceptance of New Meningococcal Jab BLA
NASDAQ · 04/17 12:14
Weekly Report: what happened at ENTX last week (0408-0412)?
Weekly Report · 04/15 11:59
Veru, Theravance Biopharma, Adial Pharmaceuticals among healthcare movers
Seeking Alpha · 04/12 14:00
Here's Why You Should Invest in Entera Bio (ENTX) Stock Now
NASDAQ · 04/09 13:09
Entera Bio Announces Publication Of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data I1n The Journal Of Bone And Mineral Research
Entera Bio's EB613 is the first oral, osteoanabolic tablet to address the treatment gap in osteoporosis. EB613 increases markers of bone formation and decreases markers of breakdown. The study was published in the Journal of Bone and Mineral Research. Entera is a leader in the development of orally delivered peptides.
Benzinga · 04/08 12:33
Weekly Report: what happened at ENTX last week (0401-0405)?
Weekly Report · 04/08 12:06
Entera Bio Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones · 04/02 13:05
Analysts Offer Insights on Healthcare Companies: Genelux Corp. (GNLX), Adicet Bio (ACET) and Entera Bio (ENTX)
3 analysts have issued buy ratings on three Healthcare sector stocks. Genelux Corp. (GNLX), Adicet Bio (ACET) and Entera Bio (ENTX) are among the 3 stocks with bullish sentiments. The 3 analysts just issued bullish reports on the Healthcare sector.
TipRanks · 04/02 10:30
Weekly Report: what happened at ENTX last week (0325-0329)?
Weekly Report · 04/01 12:02
Weekly Report: what happened at ENTX last week (0318-0322)?
Weekly Report · 03/25 12:06
Weekly Report: what happened at ENTX last week (0311-0315)?
Weekly Report · 03/18 12:04
Weekly Report: what happened at ENTX last week (0304-0308)?
Weekly Report · 03/11 11:59
Entera Bio Ltd Shares Financial Update for Investor Awareness
TipRanks · 03/08 21:23
Entera Bio FY23 EPS $(0.31) Vs $(0.41) YoY; As Of December 31, 2023, Entera Had Cash And Cash Equivalents Of $11.0M
As of December 31, 2023, Entera had cash and cash equivalents of $11.0 million. The Company believes its existing cash resources will be sufficient to meet its projected operating requirements through the second quarter of 2025. Entera reported a net loss of $8.9 million for the year ended December 31,. 2023.
Benzinga · 03/08 21:17
Entera Bio GAAP EPS of -$0.31 beats by $0.01
Seeking Alpha · 03/08 21:13
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
Barchart · 03/08 15:05
Entera Bio Ltd. Maintains Nasdaq Listing with Price Compliance
TipRanks · 03/04 13:42
Weekly Report: what happened at ENTX last week (0226-0301)?
Weekly Report · 03/04 12:02
More
Webull provides a variety of real-time ENTX stock news. You can receive the latest news about Entera Bio Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ENTX
Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.